MTHFD2

Across TCGA pan-cancer cohorts, MTHFD2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MTHFD2 data layer compared with 29 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MTHFD2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MTHFD2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LSCC, CCRCC, and LUAD are the cancer types where MTHFD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.899	0.653	.014	20	view →
CCRCC	OS	Median	II,III,IV	0.327	0.917	.020	11	view →
LUAD	OS	Tertile	III,IV	0.570	0.770	.022	7	view →
GBM	DFS	Quartile	All	0.652	0.839	.027	3	view →
PDAC	DFS	Median	III,IV	0.263	0.446	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MTHFD2–LSCC (DFS)

Open the LSCC breakdown →